Lacrimal gland repair using progenitor cells
Lacrimal gland repair using progenitor cells
批准号:
9009875
负责人:
Helen P. Makarenkova
金额:
$67.76万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-01-01 至 2020-12-31
关键词:
AdultAffectAgeAmericanAutoimmune ProcessBiologicalBirthBreedingCD34 geneCell LineageCell TransplantationCell TransplantsCell physiologyCellsChronicClinicalDataDevelopmentDiseaseDisease ProgressionDuctalDuctal Epithelial CellEpithelialEpithelial CellsEye diseasesFemaleFunctional disorderGene ExpressionGenetic RecombinationGlandGoalsHumanImageInfiltrationInflammationInflammatoryLabelLacrimal gland structureLife StyleMaintenanceMolecularMorphogenesisMouse StrainsMusMyoepithelialMyoepithelial cellNeuronsPTPRC genePathogenesisPatientsPopulationProto-Oncogene Protein c-kitReplacement TherapyReporterSignal TransductionSjogren&aposs SyndromeSmooth Muscle Actin Staining MethodSorting - Cell MovementSpatial DistributionStagingStem cellsSystemTACSTD1 geneTamoxifenTestingTherapeuticThrombospondin 1TimeTissuesTransplantationVisual AcuityWorkaqueouseffective therapyeye drynessfunctional restorationin vivoinjuredirritationloss of functionmonolayermouse modelnovelnovel therapeuticsocular surfacepluripotencyprogenitorpublic health relevancerepairedstemthree dimensional cell culturetool
中文摘要
描述(由申请人提供):水缺乏性干眼(ADDE)的特征是泪腺(LG)缺乏泪液分泌。目前,ADDE没有治愈方法,也没有令人满意的治疗方法。了解人类ADDE发病机制的挑战之一是无法在出现明显临床体征之前进行生物学和分子研究。因此,仍然很难理解疾病发展的确切步骤。该提案的目标是跟踪干细胞和祖细胞的命运在组织维护和疾病,并确定最佳的祖细胞修复“患病”的LG。我们建议使用最近开发的TSP-1-/-小鼠,完全模仿自身免疫性干眼病的慢性发展与功能丧失之前的细胞炎症细胞浸润。我们提出了新的想法,LG有两个功能不同的
祖细胞群:成年LG的EPCP和MECP含有共同的(或双能的)干/祖细胞,能够产生EPC和MEC细胞谱系。我们将在体内跟踪每种细胞谱系,并确定MECP或EPCP是否具有产生腺泡、导管和MEC的共同干/祖细胞或谱系特异性祖细胞。我们还将研究“患病”LG中MECP和EPCP细胞的命运,并测试正常MECP和EPCP恢复“患病”LG功能的能力。我们最近的数据显示,在从小鼠LG分选的c-kit阳性上皮细胞(EPC)群体中,c-kit+dim/EpCAM+/Sca 1-/CD 34-/CD 45-细胞是推定的上皮(腺泡和导管)细胞祖细胞(EPCP)群体。分离的EPCP表达多能性因子和上皮细胞谱系Runx 1和EpCAM的标志物,并且当在重新聚集的3D培养物中生长时形成分支。当移植到受伤或患病的LG时,它们恢复了LG的功能性腺泡和导管上皮成分。我们还发现,肌上皮细胞(MEC)具有高水平的可塑性,能够分化为神经元、内皮细胞、新的他莫昔芬诱导的上皮和肌上皮谱系特异性报告小鼠的可用性允许我们直接分离MEC/MECP和EPC/MECP。来自健康和患病LG的EPCP用于形态、功能和基因表达分析,以及用于祖细胞纯化和移植。我们的研究将为使用LG祖细胞进行细胞替代疗法治疗无法有效治疗或治愈的干眼病提供概念证明。我们的工作也将为治疗ADDE开辟新的治疗可能性。
英文摘要
DESCRIPTION (provided by applicant): Aqueous deficiency dry eye (ADDE) is characterized by a lack of tear secretion from the lacrimal glands (LG). Currently there is no cure and no satisfactory treatment for ADDE. One of the challenges of understanding the mechanism of human ADDE pathogenesis is the inability to perform the biological and molecular studies prior to obvious clinical signs. As a result, it remains difficult to understand the precise steps of disease development. The goal of this proposal is to track stem and progenitor cell fate during tissue maintenance and disease and to identify the optimum progenitor cells to repair the "diseased" LG. We propose to use the recently developed TSP-1-/- mice that fully mimic the chronic development of autoimmune dry eye disease with loss of function preceding cellular inflammatory cell infiltration. We propose the novel idea that the LG has two functionally distinct
progenitor cell populations: EPCP and MECP of the adult LG contains common (or bipotent) stem/progenitor cells able to give rise to both EPC and MEC cell lineages. We will follow each cell lineage in vivo and determine whether the MECP's or EPCP's have a common stem/progenitor cell producing acinar, ductal, and MEC's or a lineage specific progenitor. We will also investigate the fate of MECP's and EPCP's cells in `diseased' LG's and test the ability of normal MECP's and EPCPs to restore the function of `diseased' LG's. Our recent data shows that among c-kit-positive epithelial cell (EPC) populations sorted from mouse LG the c-kit+dim/EpCAM+/Sca1-/CD34-/CD45- cells are a putative epithelial (acinar and ductal) cell progenitor (EPCP) population. Isolated EPCP's express pluripotency factors and markers of the epithelial cell lineage Runx1 and EpCAM and form branches when grown in reaggregated 3D cultures. When transplanted into injured or diseased LG's, they restore the functional acinar and ductal epithelial component of the LG. We also found that myoepithelial cells (MEC's) have a high level of plasticity and are able to differentiate into neuronal, endothelial, and MEC lineages Availability of new tamoxifen- inducible epithelial and myoepithelial lineage specific-reporter mice allows us to directly isolate MEC's/MECP's and EPC's/EPCP's from the healthy and diseased LG's for morphological, functional and gene expression analyses, and also for progenitor cell purification, and transplantation. Our study will provide proof of concept for use f LG progenitor cells in cell replacement therapy for dry eye diseases that have no effective treatment or cure. Our work would also open up new therapeutic possibilities to treat ADDE.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Salivary gland ionocyte organization and function during homeostasis, repair, and disease
-
批准号:10471333
-
项目类别:
-
资助金额:$58.15万
-
财政年份:2021
-
负责人:Helen P. Makarenkova
-
依托单位:
Salivary gland ionocyte organization and function during homeostasis, repair, and disease
-
批准号:10628001
-
项目类别:
-
资助金额:$59.64万
-
财政年份:2021
-
负责人:Helen P. Makarenkova
-
依托单位:
Salivary gland ionocyte organization and function during homeostasis, repair, and disease
-
批准号:10279604
-
项目类别:
-
资助金额:$62.77万
-
财政年份:2021
-
负责人:Helen P. Makarenkova
-
依托单位:
FGF signaling in lacrimal gland homeostasis, regeneration and disease
-
批准号:9891063
-
项目类别:
-
资助金额:$46.82万
-
财政年份:2018
-
负责人:Helen P. Makarenkova
-
依托单位:
Lacrimal Gland Repair Using Progenitor Cells
-
批准号:10661511
-
项目类别:
-
资助金额:$41.64万
-
财政年份:2016
-
负责人:Helen P. Makarenkova
-
依托单位:
Lacrimal Gland Repair Using Progenitor Cells
-
批准号:10436876
-
项目类别:
-
资助金额:$39.77万
-
财政年份:2016
-
负责人:Helen P. Makarenkova
-
依托单位:
Lacrimal Gland Repair Using Progenitor Cells
-
批准号:10211751
-
项目类别:
-
资助金额:$41.0万
-
财政年份:2016
-
负责人:Helen P. Makarenkova
-
依托单位:
Lacrimal gland repair using progenitor cells
-
批准号:9199215
-
项目类别:
-
资助金额:$61.45万
-
财政年份:2016
-
负责人:Helen P. Makarenkova
-
依托单位:
Regulation of lacrimal gland development and regeneration
-
批准号:8217219
-
项目类别:
-
资助金额:$23.74万
-
财政年份:2011
-
负责人:Helen P. Makarenkova
-
依托单位:
Regulation of lacrimal gland development and regeneration
-
批准号:8029664
-
项目类别:
-
资助金额:$23.74万
-
财政年份:2011
-
负责人:Helen P. Makarenkova
-
依托单位:
Role of homeobox proteins in muscle development
-
批准号:7492200
-
项目类别:
-
资助金额:$33.47万
-
财政年份:2007
-
负责人:Helen P. Makarenkova
-
依托单位:
Role of homeobox proteins in muscle development
-
批准号:8115925
-
项目类别:
-
资助金额:$31.81万
-
财政年份:2007
-
负责人:Helen P. Makarenkova
-
依托单位:
Role of homeobox proteins in muscle development
-
批准号:7884596
-
项目类别:
-
资助金额:$33.14万
-
财政年份:2007
-
负责人:Helen P. Makarenkova
-
依托单位:
Role of homeobox proteins in muscle development
-
批准号:7673582
-
项目类别:
-
资助金额:$33.47万
-
财政年份:2007
-
负责人:Helen P. Makarenkova
-
依托单位:
海外基金